Bergenbio ASA
- Country
- 🇳🇴Norway
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 16
- Market Cap
- -
- Website
- http://www.bergenbio.com
Clinical Trials
18
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
A Study to Investigate 14C-bemcentinib in Healthy Male Subjects
- Conditions
- Non-Small Cell Lung CancerMyelodysplastic SyndromesMetastatic Pancreatic CancerGlioblastomaMalignant MesotheliomaCOVID-19Metastatic MelanomaAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- BerGenBio ASA
- Target Recruit Count
- 6
- Registration Number
- NCT06469138
- Locations
- 🇬🇧
Labcorp Clinical Research Unit Ltd., Leeds, United Kingdom
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BerGenBio ASA
- Target Recruit Count
- 26
- Registration Number
- NCT05469178
- Locations
- 🇫🇷
Hôpital prive du Confluent SAS, Departement d'oncologie, Nantes Cedex 2, France
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants
- Conditions
- Ovarian Neoplasms
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- BerGenBio ASA
- Target Recruit Count
- 16
- Registration Number
- NCT04893551
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Yonsei University Health System- Severance Hospital, Seoul, Korea, Republic of
A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- BerGenBio ASA
- Target Recruit Count
- 115
- Registration Number
- NCT04890509
- Locations
- 🇮🇳
Unity Trauma Center and ICU, Unity Hospital, Surat, Gujarat, India
🇿🇦Lakeview Hospital, Mowbray, Benoni, South Africa
🇮🇳Kasturba Medical College, Mangalore, Karnataka, India
A First-time-in-human Study of BGB149
- Conditions
- Healthy Volunteers
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- BerGenBio ASA
- Target Recruit Count
- 24
- Registration Number
- NCT03795142
- Locations
- 🇬🇧
Parexel Northwick Park, London, Harrow, Middlesex, United Kingdom
- Prev
- 1
- 2
- Next
News
BerGenBio's AXL Inhibitor Shows Promise in STK11-Mutated Lung Cancer, Faces Leadership Transition
BerGenBio highlights a significant unmet need in STK11-mutated lung cancer, a substantial market opportunity for its AXL inhibitor, bemcentinib.
BerGenBio's AXL Inhibitor Receives FDA Fast Track for STK11-Mutated Cancers Amidst Leadership Transition
BerGenBio's AXL inhibitor receives FDA Fast Track designation, highlighting its potential in treating STK11-mutated cancers, addressing a significant unmet medical need.